ELI LILLY
US stocks face crucial test as AI earnings, Fed meeting loom
US stocks face a crucial week as earnings from Alphabet, Microsoft and Amazon coincide with the Federal Reserve’s policy decision. Investors will assess whether massive AI investments can deliver sustainable returns, while the Fed’s guidance on interest rates and uncertainty surrounding the November midterm elections could shape market sentiment and volatility.
US Stock Market prediction: S&P 500, Nasdaq, Dow Jones look to rebound as Wall Street investors set to be driven by a few factors, top stocks to follow
US Stock Market today: Investors also have their focus trained on the US midterm elections on November 3, with growing bets that the Democrats will wrest control of the US Congress away from President Donald Trump's Republican party.
Wall Street Week Ahead: Earnings flood, Fed meeting will test rickety AI market rally
US stock investors are on the edge of their seats as they anticipate quarterly earnings from tech giants like Alphabet, Microsoft, and Amazon. This week is pivotal, with the Federal Reserve meeting also in sight, likely to shape how investors feel about the AI sector. After disappointing earnings from firms such as Meta and Lam Research, mixed sentiment looms over the market, especially with the midterm elections on the horizon.
5 world market themes for the week ahead
An important week is upcoming with central banks like the Federal Reserve and European Central Bank making policy decisions. Major companies, including Alphabet, Amazon, and Microsoft, are set to report their earnings. Political events are also significant, with elections in Israel and Brazil influencing markets. China's leadership will hold discussions focused on party governance amidst external pressures.
GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says
The China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimates. Improving affordability, generic launches and wider access could drive adoption, though penetration remains low, particularly in India, where cost concerns and cultural resistance to injectable treatments remain key barriers.
Ozempic wave boosts US cobblers and tailors as Americans tighten their belts
Consumers in the US are experiencing significant changes in their wardrobes due to weight-loss medications. Many individuals are opting for alterations instead of purchasing new clothing items. This trend is impacting various services, including cobblers and tailors. Discount stores and thrift shops are also benefiting from the rise in GLP-1 drug users. As clothing sizes fluctuate, many people seek more affordable wardrobe options while adjusting to their new sizes.
- Go To Page 1
Beauty firms chase 'Ozempic face' market as weight-loss drugs boom
Galderma, Natura, and L'Oreal are developing treatments for consumers experiencing facial sagging due to rapid weight loss. These companies are responding to increased demand linked to the popularity of GLP-1 obesity drugs. Experts indicate that rapid weight loss may lead to skin laxity and diminished facial volume. While existing treatments show promise, some limitations remain in addressing deeper facial structure issues.
US stocks today: US stocks end higher as healthcare stocks lift Dow, tech a breather
Wall Street ended higher on Tuesday, led by the Dow as investors shifted towards healthcare and other value stocks. The S&P 500 also gained, while the Nasdaq slipped as technology stocks paused after a rebound in the previous session. Healthcare shares gained, while small-caps and defensive sectors also outperformed.
US stocks today: US stocks gain as healthcare stocks hit record high, oil prices fall
Wall Street's main indexes saw increases driven by a rally in healthcare stocks that reached record highs. Easing oil prices contributed to a recovery from the previous week's technology led selloff. Major companies like General Motors and Steel Dynamics reported disappointing earnings forecasts, while 3M and Equifax exceeded expectations. Investors are closely monitoring upcoming corporate earnings reports from several high-profile companies.
D-St set for a positive opening as GIFT Nifty signals firm start
On Thursday, market indices Nifty and Sensex experienced notable advances, illustrating a surge in local investor confidence. The Nifty surpassed the 23,000 mark, buoyed by strong domestic demand and robust tax revenue. Experts predict that the market may undergo a period of consolidation amid recovery efforts and selling pressures. While foreign portfolio investors engaged in net selling, domestic institutions stepped up as net buyers.
US Stock Market: What to led to S&P 500, Nasdaq, Dow Jones, Russell 2000 rebound after historic low despite fall of Nvidia stocks, TSMC shares?
US Stock Market today: Nvidia dipped 1.8 per cent after chip manufacturer TSMC struck a cautious note on 2027 despite reporting a sixth consecutive record quarterly profit on robust AI-driven demand.
US stocks: Dow, S&P 500 end higher as traders shift from AI to healthcare
After a rocky start, the S&P 500 experienced a resurgence, largely spurred by investments in the healthcare and consumer segments. Investors seemed to distance themselves from technology stocks, anxious about mounting debts in the AI sector. Eli Lilly and UnitedHealth rose thanks to favorable evaluations from Deutsche Bank, whereas Broadcom and Nvidia struggled.
AstraZeneca strikes $40 million AI drug discovery deal with insitro
AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following this, AstraZeneca will manage clinical trials and further development. This collaboration signifies insitro's growing presence in the pharmaceutical industry.
AstraZeneca strikes $40 million AI drug discovery deal with insitro
AstraZeneca has entered into a partnership with insitro to identify treatments for challenging liver and heart diseases. This collaboration, which involves a $40 million upfront payment, could reach $1.46 billion in total milestones. The companies aim to tackle metabolic dysfunction-associated steatohepatitis and cardiomyopathies through insitro's AI platform.
Assessing products to counter side effects of GLP-1, says Bayer's Triana
Bayer AG plans to expand its consumer health business in India significantly by 2030. The company aims to triple its revenue in the Indian market during this period. Bayer is specifically targeting opportunities in digestive health, nutrition, and multivitamins related to GLP-1 drug side effects. Additionally, Bayer will develop products locally and seek manufacturing partnerships to enhance their market presence.
Our central mission must be patient-centric innovation: JP Nadda
J P Nadda urges industry to take discoveries ‘from bench to bedside’ as the FICCI–Lilly Bharat Life Sciences Award backs its inaugural cohort with ₹7 crore in grants
India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO
Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO
Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.
From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India
India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry sources said both have been submitted to Indian regulators, potentially expanding demand beyond injectable treatments.
Women tip the scale as weight-loss boom reaches tier-II cities
While startups such as General Catalyst-backed Voy and Mumbai-based Metago are seeing higher demand from women, Elevate Now, backed by Titan Capital, has an almost equal mix of men and women among its customers.
Kerala HC says exorbitant drug prices can trigger government intervention in patented medicines
The Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the Centre to gather data on the affordability of specific life-saving drugs. This ruling addresses access issues for two breast cancer medications, abemaciclib and ribociclib. The decision empowers the government to consider invoking Section 100 of the Patents Act for affordable access.
Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9
Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers all markets globally except for the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor, will be marketed under the name Lyrokaul in Europe.
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.
GLP-1 users are suing over vision loss: What does the evidence really show?
Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately warned about the risk of a rare type of sudden vision loss, ABC News reported.
Ozempic maker Novo Nordisk sets sights on hair-loss market
The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.
Smart ring maker Oura, shareholders look to raise up to $2.2 billion in US IPO
Smart ring maker Oura plans to raise up to $2.2 billion in its US initial public offering. Eli Lilly and Dragoneer have indicated interest in purchasing shares in the offering. Oura and some existing investors will sell 50 million shares priced between $40 and $44. The company makes a smart ring that tracks key health indicators like heart rate and sleep.
Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs
Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is crucial for Novo to navigate patent challenges and competitive threats with a transparent and strategic approach.
US listing could put Japan's Kioxia in global AI spotlight, Voya's Thomas says
Kioxia's plan for a US stock listing could attract global investors. This move aims to expand the Japanese chipmaker's investor base significantly. A US listing may improve liquidity for Japanese tech firms like Kioxia. This is important for large AI-focused funds seeking investment opportunities. Such listings make it easier for funds to invest in promising companies.
Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit
Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This development highlights the expanding medical potential of these widely used drugs.
Load More
